Testing effectiveness (Phase 2)WithdrawnNCT03013387What this trial is testingDosimetry Guided PRRT With 90Y-DOTATOCWho this might be right forNeuroendrocrine TumorsMeningiomaNeuroblastoma+1 more Sue O'Dorisio
Testing effectiveness (Phase 2)Active Not RecruitingNCT04471727What this trial is testingA Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)Who this might be right forSmall-Cell Lung CancerNeuroendocrine Carcinoma Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 232